Todorova Valentina K, Wei Jeanne Y, Makhoul Issam
Division of Medical Oncology/Department of Internal Medicine, University of Arkansas for Medical Sciences Little Rock, Arkansas, USA.
Department of Geriatrics, University of Arkansas for Medical Sciences Little Rock, Arkansas, USA.
Am J Cancer Res. 2021 Sep 15;11(9):4070-4091. eCollection 2021.
Doxorubicin (DOX) is a highly effective chemotherapy agent that often causes cardiotoxicity. Despite a number of extensive studies, the risk for DOX cardiotoxicity remains unpredictable. The majority of the studies on DOX-induced cardiotoxicity have been focused on the effects on cardiomyocytes that lead to contractile dysfunction. The roles of systemic inflammation, endothelial injury and neutrophil recruitment, all induced by the DOX, are increasingly recognized as the mechanisms that trigger the development and progression of DOX-induced cardiomyopathy. This review explores recent data regarding the possible mechanisms and biomarkers of early subclinical DOX-associated cardiotoxicity.
阿霉素（DOX）是一种高效的化疗药物，但常常会导致心脏毒性。尽管进行了大量广泛的研究，但DOX心脏毒性的风险仍然无法预测。大多数关于DOX诱导心脏毒性的研究都集中在对心肌细胞的影响上，这些影响会导致收缩功能障碍。由DOX诱导的全身炎症、内皮损伤和中性粒细胞募集的作用，越来越被认为是引发DOX诱导的心肌病发展和进展的机制。这篇综述探讨了关于早期亚临床DOX相关心脏毒性的可能机制和生物标志物的最新数据。
